Sign Out
No formal interaction studies with Actilyse and medicinal products commonly administered in patients with acute myocardial infarction have been performed.
Concomitant use of GPIIb/IIIa antagonists increases the risk of bleeding.
Drugs affecting coagulation/platelet function: The risk of haemorrhage is increased if coumarine derivatives, oral anticoagulants, platelet aggregation inhibitors, unfractionated heparin or LMWH or active substances which interfere with coagulation are administered (before, during or within the first 24 hours after treatment with Actilyse) (see Contraindications).
ACE inhibitors: Concomitant treatment with ACE inhibitors may enhance the risk of suffering a hypersensitivity reaction (see Precautions).
